“Cancer patients using cannabis report better influence from the plant extract them from synthetic products.”
While there have been several studies in the past of marijuana cannabinoids positive effects on different forms of cancer, those studies have primarily been performed with synthetic cannabinoids. As marijuana is still considered a “scheduled one substance” within the controlled substance act, performing any studies with natural cannabinoids is still currently prohibited in United States. Fortunately for the world’s medical marijuana community, researchers at the Division of Oncology – Integrated Oncology and Palliative Care in Haifa, Israel – have no such restrictions.
Offering more comprehensive research in a recently published edition of “Evidence-Based Complementary and Alternative Medicine” the Israeli scientists discovered that the consumption of natural cannabinoids resulted in a “significant improvement” for “all cancer or anticancer treatment related symptoms.”
no images were found
As should be expected…the scientist went on to report;
“cancer patients using cannabis report better influence from the plant extract them from synthetic products. However, almost all the research conducted to date has been performed with synthetic products.”
As a means of addressing this fundamental flaw, the Israeli scientists were careful to utilize natural cannabinoids, performed on human participants – rather than synthetic derivatives on some unsuspecting lab rat.
“The cannabis plant and the synthetic drugs based on the plant are considered medically safe. Most of the adverse effects are related to the fact that the plant and the drugs are psychoactive, mostly depending on their concentration and on the Δ9-THC dosage.”
This new comprehensive study indicates;
“vaporized cannabis in subjects who experienced neuropathic pain despite traditional treatment,” was vastly improved, and that “the study included 39 patients with central and peripheral neuropathic pain. The vaporized cannabis, even at low doses, showed analgesic efficacy with minimal psychoactive effects and may present an effective option for patients with treatment-resistant neuropathic pain. In the current study, the number of patients with severe pain (grade 3-4) was cut by half.”
The overall conclusion was that “the positive effects of cannabis on various cancer related symptoms… should push the use of cannabis in the practice of oncology palliative treatment.”